HIMS Stock Soars 40% on Novo Nordisk Partnership Deal
💡 Key Takeaway
The new deal removes a major legal overhang and provides a clear growth path for HIMS, but its volatile history with Novo Nordisk warrants a cautious approach.
From Foes to Partners: The HIMS-NVO Deal
Shares of Hims & Hers Health (HIMS) skyrocketed nearly 40% after the company announced a surprise agreement with pharmaceutical giant Novo Nordisk (NVO). The deal will see HIMS sell Novo's popular GLP-1 weight loss drugs, Ozempic and Wegovy, on its telemedicine platform.
This partnership marks a dramatic turnaround for the two companies, which have had a tumultuous relationship. They formed a short-lived partnership last year that ended acrimoniously when Novo Nordisk accused HIMS of illegally selling compounded versions of its drugs.
The conflict escalated earlier this year when Novo Nordisk sued HIMS after the telehealth company announced plans to sell a lower-cost version of the Wegovy pill. HIMS had argued its personalized versions were legally permissible and beneficial for patients, especially during drug shortages.
As part of the new agreement, the lawsuit will be dropped. HIMS will now prominently offer the branded Ozempic and Wegovy drugs, while only providing compounded versions in limited, medically necessary circumstances without actively marketing them.
Why This Deal is a Game-Changer for HIMS
This deal is critically important because it removes one of the biggest uncertainties hanging over HIMS stock. The legal battle with a major pharmaceutical company was a significant risk that has now been resolved, de-risking the investment thesis.
For HIMS, gaining official access to the blockbuster GLP-1 drug category is a major growth driver. Weight loss drugs represent one of the hottest markets in healthcare, and this partnership legitimizes HIMS's position in this space.
However, investors should note that selling branded drugs will likely come at lower gross margins compared to the compounded versions HIMS was previously selling. This trade-off—higher revenue volume but potentially lower profitability per sale—will be key to watch.
The fact that Novo Nordisk, a global pharma leader, was willing to return to the negotiating table also validates the reach and value of HIMS's telemedicine platform. This endorsement could pave the way for similar partnerships with other drugmakers.
Source: The Motley FoolAnalysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
HIMS presents a compelling opportunity for growth-oriented investors, but position size should be controlled given the partnership's volatile history.
The stock remains reasonably valued with a forward P/E under 20, and revenue growth of 28% last quarter shows strong execution. The international expansion opportunity provides additional upside, though the rocky history with Novo Nordisk necessitates caution.
What This Means for Me
